163 related articles for article (PubMed ID: 34556806)
41. Insulin-like growth factor-I enhances lymphoid and myeloid reconstitution after allogeneic bone marrow transplantation.
Alpdogan O; Muriglan SJ; Kappel BJ; Doubrovina E; Schmaltz C; Schiro R; Eng JM; Greenberg AS; Willis LM; Rotolo JA; O'Reilly RJ; van den Brink MR
Transplantation; 2003 Jun; 75(12):1977-83. PubMed ID: 12829897
[TBL] [Abstract][Full Text] [Related]
42. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B
Front Immunol; 2020; 11():181. PubMed ID: 32117306
[TBL] [Abstract][Full Text] [Related]
43. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease.
Krijanovski OI; Hill GR; Cooke KR; Teshima T; Crawford JM; Brinson YS; Ferrara JL
Blood; 1999 Jul; 94(2):825-31. PubMed ID: 10397751
[TBL] [Abstract][Full Text] [Related]
44. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
[TBL] [Abstract][Full Text] [Related]
45. HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease.
Li J; Heinrichs J; Haarberg K; Semple K; Veerapathran A; Liu C; Anasetti C; Yu XZ
J Immunol; 2015 Jul; 195(2):717-25. PubMed ID: 26048147
[TBL] [Abstract][Full Text] [Related]
46. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
Yang YG; Sergio JJ; Pearson DA; Szot GL; Shimizu A; Sykes M
Blood; 1997 Dec; 90(11):4651-60. PubMed ID: 9373279
[TBL] [Abstract][Full Text] [Related]
47. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
48. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L
Bone Marrow Transplant; 1990 Sep; 6(3):155-61. PubMed ID: 2252954
[TBL] [Abstract][Full Text] [Related]
49. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
[TBL] [Abstract][Full Text] [Related]
50. Separation of antileukemic effects from graft-versus-host disease in MHC-haploidentical murine bone marrow transplantation: participation of host immune cells.
Satake A; Inoue T; Kubo S; Taniguchi Y; Imado T; Fujioka T; Horiuchi M; Xu Y; Ikegame K; Yoshihara S; Kaida K; Tamaki H; Okada M; Okamura H; Ogawa H
Int J Hematol; 2010 Apr; 91(3):485-97. PubMed ID: 20300982
[TBL] [Abstract][Full Text] [Related]
51. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
Hsieh MH; Varadi G; Flomenberg N; Korngold R
Biol Blood Marrow Transplant; 2002; 8(6):303-15. PubMed ID: 12108916
[TBL] [Abstract][Full Text] [Related]
52. Transplantation of Graft Anti-Host Cytotoxic T Lymphocytes Along with Allogeneic Bone Marrow Skips Macrophage-Induced Graft-Versus-Host Disease.
Yoshida R; Yamana H; Hayashi M; Yasuda E; Shibayama Y; Hirose Y; Tanigawa N; Uchiyama K; Kubota T
J Interferon Cytokine Res; 2021 Sep; 41(9):310-318. PubMed ID: 34543129
[TBL] [Abstract][Full Text] [Related]
53. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
Chang YJ; Huang XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
[TBL] [Abstract][Full Text] [Related]
54. Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT.
Li JM; Giver CR; Waller EK
Exp Hematol; 2006 Jul; 34(7):895-904. PubMed ID: 16797417
[TBL] [Abstract][Full Text] [Related]
55. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
56. Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model.
Uckun FM; Roers BA; Waurzyniak B; Liu XP; Cetkovic-Cvrlje M
Blood; 2002 Jun; 99(11):4192-9. PubMed ID: 12010825
[TBL] [Abstract][Full Text] [Related]
57. Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation.
Auletta JJ; Eid SK; Wuttisarnwattana P; Silva I; Metheny L; Keller MD; Guardia-Wolff R; Liu C; Wang F; Bowen T; Lee Z; Solchaga LA; Ganguly S; Tyler M; Wilson DL; Cooke KR
Stem Cells; 2015 Feb; 33(2):601-14. PubMed ID: 25336340
[TBL] [Abstract][Full Text] [Related]
58. Dichotomous role of interferon-gamma in allogeneic bone marrow transplant.
Lu Y; Waller EK
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1347-53. PubMed ID: 19822293
[TBL] [Abstract][Full Text] [Related]
59. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect.
Imado T; Iwasaki T; Kuroiwa T; Sano H; Hara H
Transplantation; 2004 Feb; 77(3):391-8. PubMed ID: 14966413
[TBL] [Abstract][Full Text] [Related]
60. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.
Toubai T; Guoqing H; Rossi C; Mathewson N; Oravecz-Wilson K; Cummings E; Wu J; Sun Y; Choi S; Reddy P
Oncoimmunology; 2015 Jul; 4(7):e1016699. PubMed ID: 26140241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]